A first-in-human randomized, double-blind, placebo-controlled, single- and multiple-ascending oral dose study of novel spiroindolone KAE609, to assess the safety, tolerability and pharmacokinetics in healthy adult volunteers
Crossref DOI link: https://doi.org/10.1186/1475-2875-13-S1-O37
Published Online: 2014-09-22
Published Print: 2014-09
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Leong, Joel
Li, Ruobing
Jain, Jay Prakash
Lefèvre, Gilbert
Magnusson, Baldur
Diagana, Thierry
Pertel, Peter
Article History
First Online: 22 September 2014